Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Xeris Pharmaceuticals transferred with an Outperform at RBC Capital » 16:45
04/06/21
04/06
16:45
04/06/21
16:45
XERS

Xeris Pharmaceuticals

/

+

RBC Capital transferred…

RBC Capital transferred coverage of Xeris Pharmaceuticals to analyst Daniel Busby and kept an Outperform rating and $11 price target on the stock.

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
/

+

XERS Xeris Pharmaceuticals
/

+

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
XERS Xeris Pharmaceuticals
/

+

  • 26
    Jun
XERS Xeris Pharmaceuticals
/

+

XERS Xeris Pharmaceuticals
/

+

Over a month ago
Hot Stocks
Aytu BioScience closes merger with Neos Therapeutics » 06:16
03/22/21
03/22
06:16
03/22/21
06:16
AYTU

Aytu BioScience

$9.73 /

-0.17 (-1.72%)

, NEOS

Neos Therapeutics

$1.11 /

-0.075 (-6.36%)

, XERS

Xeris Pharmaceuticals

$4.41 /

+0.12 (+2.80%)

Aytu BioScience (AYTU)…

Aytu BioScience (AYTU) announced the closing of its merger with Neos Therapeutics (NEOS). The combined, publicly traded company will focus on maximizing its commercial portfolio of prescription therapeutics and consumer health products and building a complementary novel therapeutic development pipeline that will address significant unmet needs. The combined company has begun operating under the name Aytu BioPharma, and its shares of common stock will continue to trade on Nasdaq under the ticker "AYTU." "This merger with Neos Therapeutics transforms Aytu into a $100M revenue specialty pharmaceutical company with annualized cost synergies of $15M anticipated in 2022. With this close, we are in a strong position to enhance our footprint in pediatrics and expand our presence in adjacent specialty care segments. We also are excited to immediately start leveraging RxConnect, a best-in-class patient support program, for our product portfolio of best-in-class prescription therapeutics and consumer health products," said Josh Disbrow, CEO of Aytu BioPharma. "We greatly appreciate the support of our new and existing shareholders in supporting this merger and hope to continue this momentum of driving shareholder value." Concurrent with the closing of the merger, former Neos Therapeutics board members Beth Hecht and Jerry McLaughlin have joined the Aytu BioPharma Board of Directors. Ketan Mehta has resigned his position from the Aytu Board of Directors. Hecht currently serves as Senior Vice President, General Counsel and Corporate Secretary of Xeris Pharmaceuticals (XERS). McLaughlin most recently served as President, CEO, and member of the Board of Directors for Neos Therapeutics from 2018 until the closing of the merger with Aytu BioPharma. The closing of the merger follows the satisfaction of all customary closing conditions, including required approvals by shareholders of both Aytu and Neos at each company's Special Meeting which were each held on March 18, 2021.

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$4.41 /

+0.12 (+2.80%)

NEOS Neos Therapeutics
$1.11 /

-0.075 (-6.36%)

AYTU Aytu BioScience
$9.73 /

-0.17 (-1.72%)

AYTU Aytu BioScience
$9.73 /

-0.17 (-1.72%)

12/10/20 JMP Securities
Neos Therapeutics downgraded to Market Perform from Outperform at JMP Securities
05/29/20 H.C. Wainwright
Aytu BioScience initiated with a Buy at H.C. Wainwright
NEOS Neos Therapeutics
$1.11 /

-0.075 (-6.36%)

XERS Xeris Pharmaceuticals
$4.41 /

+0.12 (+2.80%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
XERS Xeris Pharmaceuticals
$4.41 /

+0.12 (+2.80%)

NEOS Neos Therapeutics
$1.11 /

-0.075 (-6.36%)

  • 26
    Jun
XERS Xeris Pharmaceuticals
$4.41 /

+0.12 (+2.80%)

XERS Xeris Pharmaceuticals
$4.41 /

+0.12 (+2.80%)

Hot Stocks
Iterum Therapeutics appoints Beth Hecht to board of directors » 07:56
03/16/21
03/16
07:56
03/16/21
07:56
ITRM

Iterum Therapeutics

$1.62 /

+0.07 (+4.52%)

, XERS

Xeris Pharmaceuticals

$4.54 /

-0.265 (-5.52%)

Iterum Therapeutic (ITRM)…

Iterum Therapeutic (ITRM) announced the appointment of Beth P. Hecht to the Company's Board of Directors replacing Patrick Heron, who announced he would be leaving the Board, effective as of March 12, 2021. Ms. Hecht will also serve as a member of the Audit Committee and Compensation Committee of the Board. Ms. Hecht currently serves as Senior Vice President, General Counsel and Corporate Secretary of Xeris Pharmaceuticals, Inc. (XERS).

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$4.54 /

-0.265 (-5.52%)

ITRM Iterum Therapeutics
$1.62 /

+0.07 (+4.52%)

ITRM Iterum Therapeutics
$1.62 /

+0.07 (+4.52%)

03/15/21 H.C. Wainwright
Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
12/24/20 H.C. Wainwright
Iterum CSO resignation 'somewhat troubling,' says H.C. Wainwright
06/16/20 H.C. Wainwright
Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
06/02/20 RBC Capital
Iterum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
XERS Xeris Pharmaceuticals
$4.54 /

-0.265 (-5.52%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
XERS Xeris Pharmaceuticals
$4.54 /

-0.265 (-5.52%)

ITRM Iterum Therapeutics
$1.62 /

+0.07 (+4.52%)

  • 26
    Jun
XERS Xeris Pharmaceuticals
$4.54 /

-0.265 (-5.52%)

ITRM Iterum Therapeutics
$1.62 /

+0.07 (+4.52%)

XERS Xeris Pharmaceuticals
$4.54 /

-0.265 (-5.52%)

Syndicate
Xeris Pharmaceuticals raises $27M in a registered direct offering » 07:16
03/11/21
03/11
07:16
03/11/21
07:16
XERS

Xeris Pharmaceuticals

$4.33 /

-0.28 (-6.07%)

Xeris Pharmaceuticals…

Xeris Pharmaceuticals announced the pricing of a registered direct offering of 6,553,398 shares of common stock, par value $0.0001 per share, to funds managed by Deerfield Management Company, L.P., which are existing investors in the Company, at a purchase price of $4.12 per share, resulting in gross proceeds of $27.0 million. The offering is being made without an underwriter or a placement agent and as a result the Company will not be paying any underwriting discounts in connection with this offering.

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$4.33 /

-0.28 (-6.07%)

XERS Xeris Pharmaceuticals
$4.33 /

-0.28 (-6.07%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
XERS Xeris Pharmaceuticals
$4.33 /

-0.28 (-6.07%)

  • 26
    Jun
XERS Xeris Pharmaceuticals
$4.33 /

-0.28 (-6.07%)

XERS Xeris Pharmaceuticals
$4.33 /

-0.28 (-6.07%)

Earnings
Xeris Pharmaceuticals reports Q4 EPS (41c), consensus (38c) » 07:05
03/09/21
03/09
07:05
03/09/21
07:05
XERS

Xeris Pharmaceuticals

$4.71 /

-0.12 (-2.48%)

Reports Q4 revenue $7.1M,…

Reports Q4 revenue $7.1M, consensus $8.21M. "Despite the obvious challenges of 2020, I believe it was a very successful year for Xeris, and in particular, the fourth quarter. We saw continuous growth in demand for Gvoke throughout the year with quarter over quarter increases in prescriptions and market share, which was accelerated by the launch of Gvoke HypoPen in July, and we did so while operating our commercial organization virtually for 10 months of the year. We also reported positive clinical data in several clinical programs, we put more cash on the balance sheet, and equitized a large portion of our convertible debt," said Paul R. Edick, Chairman and CEO. "Looking ahead, we are poised to steadily grow Gvoke, advance partnership discussions for Ogluo in ex-US territories, find development and commercialization partners for select pipeline programs, and advance our technology platforms, XeriSol(TM) and XeriJect(TM), through internal development and external partnerships."

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$4.71 /

-0.12 (-2.48%)

XERS Xeris Pharmaceuticals
$4.71 /

-0.12 (-2.48%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
XERS Xeris Pharmaceuticals
$4.71 /

-0.12 (-2.48%)

  • 26
    Jun
XERS Xeris Pharmaceuticals
$4.71 /

-0.12 (-2.48%)

XERS Xeris Pharmaceuticals
$4.71 /

-0.12 (-2.48%)

On The Fly
Fly Intel: Wall Street's top stories for Friday » 16:15
02/12/21
02/12
16:15
02/12/21
16:15
DIS

Disney

$187.69 /

-3.27 (-1.71%)

, EXPE

Expedia

$146.49 /

-3.13 (-2.09%)

, IIVI

II-VI

$89.82 /

-9.81 (-9.85%)

, COHR

Coherent

$257.89 /

+31.66 (+13.99%)

, LITE

Lumentum

$94.00 /

+1.41 (+1.52%)

, MKSI

MKS Instruments

$167.45 /

+5.23 (+3.22%)

, MRNA

Moderna

$183.60 /

+0.18 (+0.10%)

, PFE

Pfizer

$34.72 /

+0.29 (+0.84%)

, GOOG

Alphabet

$2,104.55 /

+8.99 (+0.43%)

, GOOGL

Alphabet Class A

$2,095.83 /

+6.23 (+0.30%)

, MSFT

Microsoft

$244.99 /

+0.6 (+0.25%)

, QCOM

Qualcomm

$147.98 /

+2.53 (+1.74%)

, NVDA

Nvidia

$598.42 /

-11.89 (-1.95%)

, XERS

Xeris Pharmaceuticals

$6.84 /

+0.22 (+3.32%)

, IMGN

ImmunoGen

$10.51 /

+2.405 (+29.67%)

, HUBS

HubSpot

$501.62 /

+69.38 (+16.05%)

, FOLD

Amicus

$12.56 /

-6.2 (-33.05%)

, LLNW

Limelight Networks

$3.96 /

-0.6 (-13.16%)

, NWL

Newell Brands

$24.19 /

-1.85 (-7.10%)

The major averages closed…

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

MKSI MKS Instruments
$167.45 /

+5.23 (+3.22%)

LLNW Limelight Networks
$3.96 /

-0.6 (-13.16%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

IMGN ImmunoGen
$10.51 /

+2.405 (+29.67%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

HUBS HubSpot
$501.62 /

+69.38 (+16.05%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

02/12/21 Loop Capital
Disney price target raised to $230 from $190 at Loop Capital
02/12/21 Evercore ISI
Disney price target raised to $210 from $200 at Evercore ISI
02/12/21 JPMorgan
Disney price target raised to $220 from $210 at JPMorgan
02/12/21 Credit Suisse
Disney price target raised to $218 from $192 at Credit Suisse
EXPE Expedia
$146.49 /

-3.13 (-2.09%)

02/12/21 Stifel
Expedia price target raised to $140 from $117 at Stifel
02/12/21 Cowen
Expedia price target raised to $150 from $140 at Cowen
02/12/21 Benchmark
Expedia price target raised to $175 from $120 at Benchmark
02/12/21 Barclays
Expedia price target raised to $167 from $140 at Barclays
IIVI II-VI
$89.82 /

-9.81 (-9.85%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
COHR Coherent
$257.89 /

+31.66 (+13.99%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
LITE Lumentum
$94.00 /

+1.41 (+1.52%)

MKSI MKS Instruments
$167.45 /

+5.23 (+3.22%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

02/03/21 Piper Sandler
Moderna's vaccine approved in Singapore, says Piper Sandler
02/01/21
Fly Intel: Top five analyst downgrades
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Oppenheimer
Moderna price target raised to $206 from $178 at Oppenheimer
PFE Pfizer
$34.72 /

+0.29 (+0.84%)

02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

02/12/21 Citi
Citi boosts Alphabet target but shares no longer a top pick
02/08/21 Stephens
Global Payments merchant business advanced by Google pact, says Stephens
02/03/21 JMP Securities
Alphabet price target raised to $2,400 from $1,700 at JMP Securities
02/03/21 JPMorgan
Alphabet price target raised to $2,390 from $2,050 at JPMorgan
GOOGL Alphabet Class A
$2,095.83 /

+6.23 (+0.30%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

02/08/21 KeyBanc
Viva reinforces Microsoft Office/Teams innovation commitment, says KeyBanc
02/08/21 RBC Capital
Datadog price target raised to $110 from $85 at RBC Capital
02/03/21 Wedbush
Cloud arms race hitting another gear with Amazon CEO move, says Wedbush
02/03/21 Jefferies
Alphabet price target raised to $2,400 from $2,150 at Jefferies
QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

02/10/21 JPMorgan
China mobile shipments data point to 'robust' Apple demand, says JPMorgan
02/08/21 JPMorgan
JPMorgan prefers shares of Qualcomm over Apple
02/04/21
Fly Intel: Top five analyst downgrades
02/04/21
Qualcomm price target raised to $150 from $126 at RBC Capital
NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

02/03/21 New Street
Nvidia upgraded to Neutral from Reduce at New Street
01/26/21 Barclays
Nvidia price target raised to $600 from $550 at Barclays
01/25/21 Citi
Citi moves Marvell up to pick in semiconductor equipment
01/15/21 Truist
Nvidia price target raised to $672 from $643 at Truist
XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
IMGN ImmunoGen
$10.51 /

+2.405 (+29.67%)

12/07/20 Piper Sandler
ImmunoGen price target raised to $6.50 from $5.50 at Piper Sandler
10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
HUBS HubSpot
$501.62 /

+69.38 (+16.05%)

02/12/21 Needham
HubSpot price target raised to $520 from $400 at Needham
02/12/21 Cowen
HubSpot price target raised to $510 from $400 at Cowen
02/12/21 Raymond James
HubSpot upgraded to Strong Buy from Outperform at Raymond James
02/12/21 Truist
HubSpot price target raised to $600 from $455 at Truist
FOLD Amicus
$12.56 /

-6.2 (-33.05%)

02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
02/12/21 Cantor Fitzgerald
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
LLNW Limelight Networks
$3.96 /

-0.6 (-13.16%)

02/12/21 Lake Street
Limelight Networks price target lowered to $6 from $9 at Lake Street
02/12/21 DA Davidson
Limelight Networks downgraded to Underperform from Neutral at DA Davidson
02/12/21 Raymond James
Limelight Networks downgraded to Market Perform from Outperform at Raymond James
02/12/21 Truist
Limelight Networks downgraded to Hold from Buy at Truist
NWL Newell Brands
$24.19 /

-1.85 (-7.10%)

02/04/21 Deutsche Bank
Newell Brands price target raised to $23 from $18 at Deutsche Bank
01/08/21 BofA
Newell Brands upgraded to Buy on shift away from home at BofA
01/08/21 BofA
Newell Brands upgraded to Buy from Neutral at BofA
01/04/21 Jefferies
Jefferies upgrades 'underappreciated' Newell Brands to Buy from Hold
XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NWL Newell Brands
$24.19 /

-1.85 (-7.10%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

MKSI MKS Instruments
$167.45 /

+5.23 (+3.22%)

LLNW Limelight Networks
$3.96 /

-0.6 (-13.16%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

IMGN ImmunoGen
$10.51 /

+2.405 (+29.67%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

HUBS HubSpot
$501.62 /

+69.38 (+16.05%)

GOOGL Alphabet Class A
$2,095.83 /

+6.23 (+0.30%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

  • 02
    Jul
  • 26
    Jun
  • 19
    May
QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

HUBS HubSpot
$501.62 /

+69.38 (+16.05%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NWL Newell Brands
$24.19 /

-1.85 (-7.10%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

IMGN ImmunoGen
$10.51 /

+2.405 (+29.67%)

IIVI II-VI
$89.82 /

-9.81 (-9.85%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

COHR Coherent
$257.89 /

+31.66 (+13.99%)

XERS Xeris Pharmaceuticals
$6.84 /

+0.22 (+3.32%)

QCOM Qualcomm
$147.98 /

+2.53 (+1.74%)

PFE Pfizer
$34.72 /

+0.29 (+0.84%)

NVDA Nvidia
$598.42 /

-11.89 (-1.95%)

MSFT Microsoft
$244.99 /

+0.6 (+0.25%)

MRNA Moderna
$183.60 /

+0.18 (+0.10%)

LLNW Limelight Networks
$3.96 /

-0.6 (-13.16%)

LITE Lumentum
$94.00 /

+1.41 (+1.52%)

GOOGL Alphabet Class A
$2,095.83 /

+6.23 (+0.30%)

GOOG Alphabet
$2,104.55 /

+8.99 (+0.43%)

FOLD Amicus
$12.56 /

-6.2 (-33.05%)

EXPE Expedia
$146.49 /

-3.13 (-2.09%)

DIS Disney
$187.69 /

-3.27 (-1.71%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:09
02/12/21
02/12
12:09
02/12/21
12:09
XERS

Xeris Pharmaceuticals

$7.08 /

+0.46 (+6.95%)

, DIS

Disney

$189.57 /

-1.39 (-0.73%)

, EXPE

Expedia

$146.81 /

-2.81 (-1.88%)

, IIVI

II-VI

$93.24 /

-6.39 (-6.41%)

, COHR

Coherent

$259.58 /

+33.35 (+14.74%)

, LITE

Lumentum

$94.62 /

+2.03 (+2.19%)

, MKSI

MKS Instruments

$167.71 /

+5.49 (+3.38%)

, MRNA

Moderna

$180.40 /

-3.02 (-1.65%)

, PFE

Pfizer

$34.85 /

+0.42 (+1.22%)

, IMGN

ImmunoGen

$10.56 /

+2.455 (+30.29%)

, HUBS

HubSpot

$503.52 /

+71.28 (+16.49%)

, FOLD

Amicus

$12.73 /

-6.03 (-32.14%)

, LLNW

Limelight Networks

$3.58 /

-0.98 (-21.49%)

, NWL

Newell Brands

$24.15 /

-1.89 (-7.26%)

The major averages are…

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

PFE Pfizer
$34.85 /

+0.42 (+1.22%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

MKSI MKS Instruments
$167.71 /

+5.49 (+3.38%)

LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

LITE Lumentum
$94.62 /

+2.03 (+2.19%)

IMGN ImmunoGen
$10.56 /

+2.455 (+30.29%)

IIVI II-VI
$93.24 /

-6.39 (-6.41%)

HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

COHR Coherent
$259.58 /

+33.35 (+14.74%)

XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
DIS Disney
$189.57 /

-1.39 (-0.73%)

02/12/21 Loop Capital
Disney price target raised to $230 from $190 at Loop Capital
02/12/21 Evercore ISI
Disney price target raised to $210 from $200 at Evercore ISI
02/12/21 JPMorgan
Disney price target raised to $220 from $210 at JPMorgan
02/12/21 Credit Suisse
Disney price target raised to $218 from $192 at Credit Suisse
EXPE Expedia
$146.81 /

-2.81 (-1.88%)

02/12/21 Stifel
Expedia price target raised to $140 from $117 at Stifel
02/12/21 Cowen
Expedia price target raised to $150 from $140 at Cowen
02/12/21 Benchmark
Expedia price target raised to $175 from $120 at Benchmark
02/12/21 Barclays
Expedia price target raised to $167 from $140 at Barclays
IIVI II-VI
$93.24 /

-6.39 (-6.41%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
02/10/21 Canaccord
II-VI price target raised to $152 from $86 at Canaccord
COHR Coherent
$259.58 /

+33.35 (+14.74%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
LITE Lumentum
$94.62 /

+2.03 (+2.19%)

MKSI MKS Instruments
$167.71 /

+5.49 (+3.38%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

02/03/21 Piper Sandler
Moderna's vaccine approved in Singapore, says Piper Sandler
02/01/21
Fly Intel: Top five analyst downgrades
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Oppenheimer
Moderna price target raised to $206 from $178 at Oppenheimer
PFE Pfizer
$34.85 /

+0.42 (+1.22%)

02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
IMGN ImmunoGen
$10.56 /

+2.455 (+30.29%)

12/07/20 Piper Sandler
ImmunoGen price target raised to $6.50 from $5.50 at Piper Sandler
10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

02/12/21 Needham
HubSpot price target raised to $520 from $400 at Needham
02/12/21 Cowen
HubSpot price target raised to $510 from $400 at Cowen
02/12/21 Raymond James
HubSpot upgraded to Strong Buy from Outperform at Raymond James
02/12/21 Truist
HubSpot price target raised to $600 from $455 at Truist
FOLD Amicus
$12.73 /

-6.03 (-32.14%)

02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
02/12/21 Cantor Fitzgerald
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

02/12/21 Lake Street
Limelight Networks price target lowered to $6 from $9 at Lake Street
02/12/21 DA Davidson
Limelight Networks downgraded to Underperform from Neutral at DA Davidson
02/12/21 Raymond James
Limelight Networks downgraded to Market Perform from Outperform at Raymond James
02/12/21 Truist
Limelight Networks downgraded to Hold from Buy at Truist
NWL Newell Brands
$24.15 /

-1.89 (-7.26%)

02/04/21 Deutsche Bank
Newell Brands price target raised to $23 from $18 at Deutsche Bank
01/08/21 BofA
Newell Brands upgraded to Buy on shift away from home at BofA
01/08/21 BofA
Newell Brands upgraded to Buy from Neutral at BofA
01/04/21 Jefferies
Jefferies upgrades 'underappreciated' Newell Brands to Buy from Hold
XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

PFE Pfizer
$34.85 /

+0.42 (+1.22%)

NWL Newell Brands
$24.15 /

-1.89 (-7.26%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

MKSI MKS Instruments
$167.71 /

+5.49 (+3.38%)

LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

LITE Lumentum
$94.62 /

+2.03 (+2.19%)

IMGN ImmunoGen
$10.56 /

+2.455 (+30.29%)

IIVI II-VI
$93.24 /

-6.39 (-6.41%)

HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

COHR Coherent
$259.58 /

+33.35 (+14.74%)

  • 02
    Jul
  • 26
    Jun
  • 19
    May
PFE Pfizer
$34.85 /

+0.42 (+1.22%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

IIVI II-VI
$93.24 /

-6.39 (-6.41%)

HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

COHR Coherent
$259.58 /

+33.35 (+14.74%)

XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

PFE Pfizer
$34.85 /

+0.42 (+1.22%)

NWL Newell Brands
$24.15 /

-1.89 (-7.26%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

MKSI MKS Instruments
$167.71 /

+5.49 (+3.38%)

LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

LITE Lumentum
$94.62 /

+2.03 (+2.19%)

IMGN ImmunoGen
$10.56 /

+2.455 (+30.29%)

IIVI II-VI
$93.24 /

-6.39 (-6.41%)

HUBS HubSpot
$503.52 /

+71.28 (+16.49%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

COHR Coherent
$259.58 /

+33.35 (+14.74%)

XERS Xeris Pharmaceuticals
$7.08 /

+0.46 (+6.95%)

PFE Pfizer
$34.85 /

+0.42 (+1.22%)

NWL Newell Brands
$24.15 /

-1.89 (-7.26%)

MRNA Moderna
$180.40 /

-3.02 (-1.65%)

LLNW Limelight Networks
$3.58 /

-0.98 (-21.49%)

LITE Lumentum
$94.62 /

+2.03 (+2.19%)

FOLD Amicus
$12.73 /

-6.03 (-32.14%)

EXPE Expedia
$146.81 /

-2.81 (-1.88%)

DIS Disney
$189.57 /

-1.39 (-0.73%)

On The Fly
Fly Intel: Pre-market Movers » 09:05
02/12/21
02/12
09:05
02/12/21
09:05
XERS

Xeris Pharmaceuticals

$6.63 /

-0.575 (-7.99%)

, NK

NantKwest

$26.00 /

-0.32 (-1.22%)

, INO

Inovio

$13.00 /

+ (+0.00%)

, DIS

Disney

$190.80 /

+1.19 (+0.63%)

, HUBS

HubSpot

$431.81 /

+7.985 (+1.88%)

, NWL

Newell Brands

$26.05 /

-0.15 (-0.57%)

, LLNW

Limelight Networks

$4.56 /

-0.08 (-1.72%)

, PLX

Protalix

$5.72 /

-0.005 (-0.09%)

, CDAK

Codiak

$24.62 /

+0.52 (+2.16%)

, SPCE

Virgin Galactic

$59.50 /

+7.18 (+13.72%)

, FUSE

Fusion Acquisition

$12.30 /

+0.54 (+4.59%)

Check out this morning's…

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

PLX Protalix
$5.72 /

-0.005 (-0.09%)

NK NantKwest
$26.00 /

-0.32 (-1.22%)

LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

INO Inovio
$13.00 /

+ (+0.00%)

HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

FUSE Fusion Acquisition
$12.30 /

+0.54 (+4.59%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

CDAK Codiak
$24.62 /

+0.52 (+2.16%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
NK NantKwest
$26.00 /

-0.32 (-1.22%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
INO Inovio
$13.00 /

+ (+0.00%)

02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
02/11/21 Oppenheimer
Inovio initiated with an Outperform at Oppenheimer
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
01/08/21 Benchmark
Inovio price target lowered to $15 from $25 at Benchmark
DIS Disney
$190.80 /

+1.19 (+0.63%)

02/12/21 Loop Capital
Disney price target raised to $230 from $190 at Loop Capital
02/12/21 Evercore ISI
Disney price target raised to $210 from $200 at Evercore ISI
02/12/21 JPMorgan
Disney price target raised to $220 from $210 at JPMorgan
02/12/21 Credit Suisse
Disney price target raised to $218 from $192 at Credit Suisse
HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

02/12/21 Needham
HubSpot price target raised to $520 from $400 at Needham
02/12/21 Cowen
HubSpot price target raised to $510 from $400 at Cowen
02/12/21 Raymond James
HubSpot upgraded to Strong Buy from Outperform at Raymond James
02/12/21 Truist
HubSpot price target raised to $600 from $455 at Truist
NWL Newell Brands
$26.05 /

-0.15 (-0.57%)

02/04/21 Deutsche Bank
Newell Brands price target raised to $23 from $18 at Deutsche Bank
01/08/21 BofA
Newell Brands upgraded to Buy on shift away from home at BofA
01/08/21 BofA
Newell Brands upgraded to Buy from Neutral at BofA
01/04/21 Jefferies
Jefferies upgrades 'underappreciated' Newell Brands to Buy from Hold
LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

02/12/21 Lake Street
Limelight Networks price target lowered to $6 from $9 at Lake Street
02/12/21 DA Davidson
Limelight Networks downgraded to Underperform from Neutral at DA Davidson
02/12/21 Raymond James
Limelight Networks downgraded to Market Perform from Outperform at Raymond James
02/12/21 Truist
Limelight Networks downgraded to Hold from Buy at Truist
PLX Protalix
$5.72 /

-0.005 (-0.09%)

12/31/20 H.C. Wainwright
Protalix data underscore value proposition for PRX-102, says H.C. Wainwright
CDAK Codiak
$24.62 /

+0.52 (+2.16%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

02/09/21 UBS
Virgin Galactic downgraded to Neutral from Buy at UBS
02/01/21
Fly Intel: Top five analyst downgrades
02/01/21 Morgan Stanley
Morgan Stanley downgrades Virgin Galactic to Equal Weight, sees 35% downside
02/01/21 Morgan Stanley
Virgin Galactic downgraded to Equal Weight from Overweight at Morgan Stanley
FUSE Fusion Acquisition
$12.30 /

+0.54 (+4.59%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

NWL Newell Brands
$26.05 /

-0.15 (-0.57%)

LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

INO Inovio
$13.00 /

+ (+0.00%)

HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

CDAK Codiak
$24.62 /

+0.52 (+2.16%)

  • 12
    Feb
  • 12
    Feb
  • 21
    Jan
  • 14
    Oct
  • 06
    Aug
  • 25
    Jun
  • 26
    Jun
  • 03
    Jun
  • 20
    May
SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

INO Inovio
$13.00 /

+ (+0.00%)

HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

NWL Newell Brands
$26.05 /

-0.15 (-0.57%)

NK NantKwest
$26.00 /

-0.32 (-1.22%)

LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

INO Inovio
$13.00 /

+ (+0.00%)

HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

CDAK Codiak
$24.62 /

+0.52 (+2.16%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

NWL Newell Brands
$26.05 /

-0.15 (-0.57%)

LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

INO Inovio
$13.00 /

+ (+0.00%)

FUSE Fusion Acquisition
$12.30 /

+0.54 (+4.59%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

Hot Stocks
Xeris Pharmaceuticals receives EC approval for Ogluo injection » 05:13
02/12/21
02/12
05:13
02/12/21
05:13
XERS

Xeris Pharmaceuticals

$6.63 /

-0.575 (-7.99%)

Xeris Pharmaceuticals…

Xeris Pharmaceuticals announced that the European Commission, or EC, has approved Ogluo injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged two years and over with diabetes mellitus. The marketing authorization is valid in all 27 countries of the European Union, plus Iceland, Norway, and Liechtenstein. As the EC decision was received after the end of the Brexit transition period, Xeris will complete a further administrative step in order to obtain a license in Great Britain. No re-examination of clinical data by the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, is expected.

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

  • 26
    Jun
XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

Over a quarter ago
Hot Stocks
Xeris in distribution pact with Megapharm for Gvoke commercialialization » 07:07
12/22/20
12/22
07:07
12/22/20
07:07
XERS

Xeris Pharmaceuticals

$5.17 /

+0.54 (+11.66%)

Xeris Pharmaceuticals…

Xeris Pharmaceuticals announced that it has entered into an exclusive distribution agreement with Megapharm Under the terms of the agreement, Megapharm will be responsible for registration and marketing of Gvoke in Israel and the Palestinian Authority, as well as named patient services supply, and Xeris will be responsible for manufacturing, product supply, quality assurance and control, regulatory support, and maintenance of IP. Gvoke is expected to be available in Israel in 2022. Gvoke will also be available in Israel prior to registration on a named patient basis starting in early 2021. "This agreement represents a major milestone in our business development strategy to expand our international distribution for Gvoke so that more insulin taking patients with diabetes can have access to it," said Paul R. Edick, Chief Executive Officer and Chairman of Xeris. "Megapharm is a well-respected marketing company with a track record of successfully commercializing innovative products in Israel, and we look forward to working with them." Miron Drucker, CEO of Megapharm, said, "We are proud to establish this partnership with Xeris to bring Gvoke to the diabetes communities in Israel and the Palestinian Authority."

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$5.17 /

+0.54 (+11.66%)

XERS Xeris Pharmaceuticals
$5.17 /

+0.54 (+11.66%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
XERS Xeris Pharmaceuticals
$5.17 /

+0.54 (+11.66%)

  • 26
    Jun
  • 12
    Feb
XERS Xeris Pharmaceuticals
$5.17 /

+0.54 (+11.66%)

XERS Xeris Pharmaceuticals
$5.17 /

+0.54 (+11.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.